Cochrane Review Group
Hypertension
56 systematic reviews in Hypertension ask 535 questions. 6.9% have no studies to answer them, 17% rest on very low certainty evidence and 39.6% reach moderate or high certainty.
Reviews
56
Questions
535
current versions
No studies
6.9%
Moderate or high
39.6%
No studies 37 · 6.9%Ungraded 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Evening vs morning dosing regimen All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | RR 0.49 [0.04, 5.42] | 1 study · 735 participants | Very low |
Evening vs morning dosing regimen Cardiovascular mortality (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | no estimate extracted | NR | No studies |
Evening vs morning dosing regimen Cardiovascular morbidity (stroke, myocardial infarction, congestive heart failure, aortic aneurysm) (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | no estimate extracted | NR | No studies |
Evening vs morning dosing regimen Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | RR 1.17 [0.53, 2.57] | 2 studies · 833 participants | Very low |
Evening vs morning dosing regimen Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | RR 0.89 [0.67, 1.2] | 7 studies · 1541 participants | Very low |
Evening vs morning dosing regimen Withdrawals from treatment due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | RR 0.76 [0.47, 1.23] | 7 studies · 1777 participants | Very low |
First‐line thiazides vs first‐line ACE inhibitors Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line beta‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line alpha‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR WDAEs · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane | RR 0.81 [0.63, 1.03] | 33 studies · 6187 participants | Very low |
Calcium supplementation/fortification vs control Adverse events (secondary outcome) · People who may be at risk for primary hypertension Calcium supplementation for prevention of primary hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Reviews 56
Effect of longer‐term modest salt reduction on blood pressure
CochraneSoF table
2 questions
Blood pressure targets for hypertension in people with diabetes mellitus
CochraneSoF table
3 questions
Pharmacotherapy for mild hypertension
CochraneSoF table
3 questions
Creatine and creatine analogues in hypertension and cardiovascular disease
CochraneSoF table
5 questions
Thiazide diuretics and the risk of hip fracture
CochraneSoF table
2 questions
Effect of early treatment with anti‐hypertensive drugs on short and long‐term mortality in patients with an acute cardiovascular event
CochraneSoF table
8 questions